Pefloxacin in lower respiratory tract infections

C. Grassi, E. Catena, G. De Iola, F. Ginesu, M. Gori, M. Lucchini, P. Mangiarotti, E. Micillo, M. Onoscuri, O. Orlandi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To determine the efficacy and safety of pefloxacin in the treatment of lower respiratory tract infections, a multicentre trial involving four departments of respiratory diseases was performed. One hundred and eight patients were admitted to the study: most of them were affected with exacerbations of chronic bronchitis or with pneumonia complicating lung cancer. Isolation and identification of responsible microorganisms from bronchial secretions was possible in 78 patients. Seven patients with withdrawn, one for worsening of the underlying disease and six for early side-effects. Thus, of 108 patients recruited, 101 completed the course of therapy (pefloxacin 400 mg bd for 5-14 days) and could be submitted to final evaluation. Of these 43 (42.6%) were cured and 48 (47.5%) showed improvement. Eradication of responsible microorganisms was achieved in 70 (90.9%) of 77 patients microbiologically evaluated. Side-effects of moderate severity were observed in 12 patients (gastrointestinal disturbances in 11 and dyspnoea in one); these did not necessitate discontinuation of therapy.

Original languageEnglish
Pages (from-to)103-110
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Volume26
Issue numberSUPPL. B
Publication statusPublished - 1990

Fingerprint

Pefloxacin
Respiratory Tract Infections
Chronic Bronchitis
Dyspnea
Multicenter Studies
Lung Neoplasms
Pneumonia
Therapeutics
Safety

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Cite this

Grassi, C., Catena, E., De Iola, G., Ginesu, F., Gori, M., Lucchini, M., ... Orlandi, O. (1990). Pefloxacin in lower respiratory tract infections. Journal of Antimicrobial Chemotherapy, 26(SUPPL. B), 103-110.

Pefloxacin in lower respiratory tract infections. / Grassi, C.; Catena, E.; De Iola, G.; Ginesu, F.; Gori, M.; Lucchini, M.; Mangiarotti, P.; Micillo, E.; Onoscuri, M.; Orlandi, O.

In: Journal of Antimicrobial Chemotherapy, Vol. 26, No. SUPPL. B, 1990, p. 103-110.

Research output: Contribution to journalArticle

Grassi, C, Catena, E, De Iola, G, Ginesu, F, Gori, M, Lucchini, M, Mangiarotti, P, Micillo, E, Onoscuri, M & Orlandi, O 1990, 'Pefloxacin in lower respiratory tract infections', Journal of Antimicrobial Chemotherapy, vol. 26, no. SUPPL. B, pp. 103-110.
Grassi C, Catena E, De Iola G, Ginesu F, Gori M, Lucchini M et al. Pefloxacin in lower respiratory tract infections. Journal of Antimicrobial Chemotherapy. 1990;26(SUPPL. B):103-110.
Grassi, C. ; Catena, E. ; De Iola, G. ; Ginesu, F. ; Gori, M. ; Lucchini, M. ; Mangiarotti, P. ; Micillo, E. ; Onoscuri, M. ; Orlandi, O. / Pefloxacin in lower respiratory tract infections. In: Journal of Antimicrobial Chemotherapy. 1990 ; Vol. 26, No. SUPPL. B. pp. 103-110.
@article{a7a563e1e6dd4affbeb5dd2cfeada9bf,
title = "Pefloxacin in lower respiratory tract infections",
abstract = "To determine the efficacy and safety of pefloxacin in the treatment of lower respiratory tract infections, a multicentre trial involving four departments of respiratory diseases was performed. One hundred and eight patients were admitted to the study: most of them were affected with exacerbations of chronic bronchitis or with pneumonia complicating lung cancer. Isolation and identification of responsible microorganisms from bronchial secretions was possible in 78 patients. Seven patients with withdrawn, one for worsening of the underlying disease and six for early side-effects. Thus, of 108 patients recruited, 101 completed the course of therapy (pefloxacin 400 mg bd for 5-14 days) and could be submitted to final evaluation. Of these 43 (42.6{\%}) were cured and 48 (47.5{\%}) showed improvement. Eradication of responsible microorganisms was achieved in 70 (90.9{\%}) of 77 patients microbiologically evaluated. Side-effects of moderate severity were observed in 12 patients (gastrointestinal disturbances in 11 and dyspnoea in one); these did not necessitate discontinuation of therapy.",
author = "C. Grassi and E. Catena and {De Iola}, G. and F. Ginesu and M. Gori and M. Lucchini and P. Mangiarotti and E. Micillo and M. Onoscuri and O. Orlandi",
year = "1990",
language = "English",
volume = "26",
pages = "103--110",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. B",

}

TY - JOUR

T1 - Pefloxacin in lower respiratory tract infections

AU - Grassi, C.

AU - Catena, E.

AU - De Iola, G.

AU - Ginesu, F.

AU - Gori, M.

AU - Lucchini, M.

AU - Mangiarotti, P.

AU - Micillo, E.

AU - Onoscuri, M.

AU - Orlandi, O.

PY - 1990

Y1 - 1990

N2 - To determine the efficacy and safety of pefloxacin in the treatment of lower respiratory tract infections, a multicentre trial involving four departments of respiratory diseases was performed. One hundred and eight patients were admitted to the study: most of them were affected with exacerbations of chronic bronchitis or with pneumonia complicating lung cancer. Isolation and identification of responsible microorganisms from bronchial secretions was possible in 78 patients. Seven patients with withdrawn, one for worsening of the underlying disease and six for early side-effects. Thus, of 108 patients recruited, 101 completed the course of therapy (pefloxacin 400 mg bd for 5-14 days) and could be submitted to final evaluation. Of these 43 (42.6%) were cured and 48 (47.5%) showed improvement. Eradication of responsible microorganisms was achieved in 70 (90.9%) of 77 patients microbiologically evaluated. Side-effects of moderate severity were observed in 12 patients (gastrointestinal disturbances in 11 and dyspnoea in one); these did not necessitate discontinuation of therapy.

AB - To determine the efficacy and safety of pefloxacin in the treatment of lower respiratory tract infections, a multicentre trial involving four departments of respiratory diseases was performed. One hundred and eight patients were admitted to the study: most of them were affected with exacerbations of chronic bronchitis or with pneumonia complicating lung cancer. Isolation and identification of responsible microorganisms from bronchial secretions was possible in 78 patients. Seven patients with withdrawn, one for worsening of the underlying disease and six for early side-effects. Thus, of 108 patients recruited, 101 completed the course of therapy (pefloxacin 400 mg bd for 5-14 days) and could be submitted to final evaluation. Of these 43 (42.6%) were cured and 48 (47.5%) showed improvement. Eradication of responsible microorganisms was achieved in 70 (90.9%) of 77 patients microbiologically evaluated. Side-effects of moderate severity were observed in 12 patients (gastrointestinal disturbances in 11 and dyspnoea in one); these did not necessitate discontinuation of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025129844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025129844&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 103

EP - 110

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. B

ER -